Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3

Status

Completed 5Terminated 2

Sponsor Class

INDUSTRY 7OTHER 2

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 43Thoracic 20Genitourinary 8Tumor-Agnostic 7Other solid neoplasm 7Breast 5Sarcoma 3Dermatologic 3Lymphoid 2Gynecologic 2Head & Neck 1CNS 1

Conditions

Solid Tumors 2Malignant Solid Tumor 2Solid Tumor 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Ramucirumab × Other solid neoplasm × Clear all
NCT02597036 2025-10-23

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
62 enrolled 25 charts
Other solid neoplasm

Solid Tumors

NCT04557384 2023-02-27

A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Terminated
3 enrolled 9 charts
Other solid neoplasm

Advanced Solid Tumor

NCT01515306 2022-03-08

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Eli Lilly and Company

Phase 2 Completed
48 enrolled 17 charts
Other solid neoplasm

Malignant Solid Tumor

NCT01634555 2019-02-26

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

Eli Lilly and Company

Phase 2 Completed
29 enrolled 12 charts
Other solid neoplasm

Solid Tumors

NCT01682135 2016-08-26

A Study in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
28 enrolled 15 charts
Other solid neoplasm

Solid Tumor

NCT01567163 2014-10-16

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

Eli Lilly and Company

Phase 2 Completed
22 enrolled 15 charts
Other solid neoplasm

Malignant Solid Tumor

NCT01005355 2014-06-18

Study of IMC-1121B in Patients With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
15 enrolled 16 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡